B2BROKER
20.10.2020 11:02:05 CEST | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the forex and crypto industry, is pleased to announce it has launched its new website and new corporate branding. This is the company’s first major website and corporate identity update and is aligned with its expansion plans to position itself as the leading global provider in its genre, having secured over 200 institutional customers to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005105/en/
Rationale
While the last few months have presented a challenging situation regarding the Covid-19 global pandemic, B2Broker noted the increases in online trading which impacted on demand for Forex and crypto-related services from brokerages. The situation served as an important trigger to move forward with the new website and branding project to provide current and potential clients access to encyclopedic information and a new experience that is an industry first.
The rationale is summed up by B2Broker Chief Operating Officer, Evgeniya Mykulyak. “We created the previous version of our website two years ago and a lot has since changed…over the course of a year, 15 team members set out to build the best website in the industry, which would not only reflect the full essence of our products, but also provide general information about the industry. Our new logo meanwhile, reflects new values and meanings that are really close to the heart of our company, our team and our products.”
New Branding
The new brand strategy involves the use of 9 circles representing the 9 product groups with the circles depicting the products being perfectly formed like circles, allowing clients to build their business like a jigsaw using the company’s products. The square surrounding the image reflects the security and stability of the company’s products, whilst the colour green represents profitability and margin and the shades - market growth and vitality.
Rollout
The new B2Broker website which has been released in 8 languages officially launched on 14th October, 2020 with clients now being referred to the new domain www.b2broker.com
Arthur Azizov, CEO B2Broker, added, “B2Broker is now in its 6th year of successful operations and our new website and branding is an important milestone in the company’s growth and development. Our newly introduced branding reflects our prime position in the industry, the breadth of technology and liquidity services we offer and the global nature of our operations. This is an exciting company with even bigger plans for the market, and now we have a state-of-the-art website and more distinctive brand that fully expresses our purpose.
About B2Broker
B2Broker’s range of products and services include: Cryptocurrency Liquidity , Forex Liquidity , CFD Liquidity , Forex Broker Turnkey , Crypto Broker Turnkey , Crypto Payment Gateway , B2Core (Trader’s Room and Back Office Software), Investment Platform , MT4 / MT5 White Label solutions , Cryptocurrency Exchange Development and www.b2bx.exchange , all of which contribute to the company’s growing presence across the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom